Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 43 (TRAJ43) is a gene segment that encodes a joining (J) region used in the somatic recombination process to generate the variable region of the T cell receptor alpha chain[5][1][8]. It is not a receptor or protein target itself, but rather a genomic element that contributes to the diversity of T cell receptors, enabling T cells to recognize a wide array of antigens presented by major histocompatibility complex (MHC) molecules[4][5]. TRAJ43 does not act as a therapeutic target, nor are there drugs or biomarker strategies specifically directed against it. It is classified as a segment of the T cell receptor (TCR) alpha locus, which, through recombination with other gene segments (V and C regions), forms the functional TCR alpha chain essential for adaptive immunity[5][1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 43 (TRAJ43).